Status:
NOT_YET_RECRUITING
Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
This study aims to evaluate the safety and pharmacokinetic characteristics after administration of DWJ1589 and DWC202315 in healty adult volunteers.
Detailed Description
The study design is a Randomized, Open-label, Oral, Single-dose, 2 × 4 crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUClast of DWJ1589 and DWC20231...
Eligibility Criteria
Inclusion
- Over 19 year old
- Healthy adult volunteers
Exclusion
- with a history of mental disorder
- For female volunteers, those who are suspected of being pregnant or lactating
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT06592495
Start Date
October 1 2024
End Date
October 1 2025
Last Update
September 23 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.